Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06307977
Other study ID # R01DA059272
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 24, 2024
Est. completion date February 2029

Study information

Verified date June 2024
Source Hunter College of City University of New York
Contact Tyrel J Starks, PHD
Phone 212-206-7919
Email tstarks@hunter.cuny.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study utilizes a randomized controlled trial design to evaluate the efficacy of couples motivational interviewing (MI) to reduce the frequency and severity of illicit drug use and frequency of HIV transmission risk behavior (TRB). Participants are randomized to one of two conditions: couples MI or standard couples HIV testing and counseling (CHTC).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 360
Est. completion date February 2029
Est. primary completion date January 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 34 Years
Eligibility Inclusion Criteria: - Have a main partner who is another cisgender male and have been in a relationship for 3 month or longer - Index participant must be between 18 and 34; Main partner can be any age 18 and older - One participant must be HIV negative (as confirmed by rapid test) - One participant must have used at least 1 drug in the past 30 days (cocaine/crack, opiates, misuse of prescription medication, stimulants, psychedelics, ecstasy, ketamine, GHB, amyl nitrite) - Index participant must have engaged in TRB in the past 30 days- Defined as CAS with a casual partner, or a serodiscordant or non-monogamous main partner - Live in the United States - Speak and read English Exclusion Criteria - Any signs of serious mental illness or cognitive deficit - Current suicidal/homicidal ideations - History of IPV with their main partner and safety concerns in the current relationship.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Couples Health Project
A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention

Locations

Country Name City State
United States University of Virginia Charlottesville Virginia
United States Wayne State University Detroit Michigan
United States Hunter College New York New York

Sponsors (2)

Lead Sponsor Collaborator
Hunter College of City University of New York National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Drug use Frequency Number of reported days of illicit drug use (amphetamines, cocaine/crack, GHB, ketamine or ecstasy) reported on quarterly timeline follow-back assessments 9 Months
Primary Urine assay for drug use Positive urine screen for drug use assessed bi-annually 9 Months
Primary CAS with casual partners Number of total anal sex acts (insertive and receptive) with casual partners reported on quarterly timeline follow-back assessments in the absence of adequate PrEP coverage 9 Months
Secondary Bacterial sexually transmitted infections Any chlamydia or gonorrhea diagnosis 9 Months
Secondary Binge Drinking Number of days on which 5 or more drinks containing alcohol were reported on the quarterly timeline follow-back interview 9 Months
Secondary PrEP Uptake self-reported receipt of a PrEP-prescription 9 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2